What this means
This is a planned trial that has not reported results yet. It will test whether NMN with TMG helps people exercise longer, compared with NMN alone.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 60–80
- Where
- 1 site, including California
The science
- Registered title
- Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
- Trial ID
- NCT07144527 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
- What is tested
- NMN and TMG (Euexia), Nicotinamide Mononucleotide (NMN), Placebo
- Sponsor
- Scott Silveira
- Ages
- 60 Years to 80 Years
- Dates
- First posted Aug 27, 2025 · updated Oct 7, 2026
Registry summary
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of nicotinamide mononucleotide (NMN) combined with trimethylglycine (TMG) supplementation, compared to NMN alone. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults.
The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels.
The supplements have been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.
Sites (1)
- Medical Office of Dr. Robert Huizenga MD, Beverly Hills, California, United States